After months of suspense, two pharmaceutical industry trade groups have agreed to drop a lawsuit against the state of Nevada over a new law that requires drug makers to report a wide array of pricing information about their diabetes medicines.
The move comes just weeks after state officials modified a regulation to allow companies to mark certain pricing data as confidential when they begin complying with the new transparency law, according to court documents.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
About the Author
